Key facts
- EpiEndo Pharmaceuticals’s last known valuation is $75.8M (Sep 2022).
- It has raised $37.0M.
- Notable investors include European Innovation Council, ABC Venture, Brunnur Ventures, Flerie, Horizon 2020 — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for EpiEndo Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for EpiEndo Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EpiEndo Pharmaceuticals
Developer of therapeutics designed to treat chronic respiratory and inflammatory disorders by improving epithelial function and host defense mechanisms. The company offers orally available macrolide-derived compounds with reduced antimicrobial resistance potential and anti-inflammatory properties, enabling patients with chronic respiratory and inflammatory conditions to reduce disease exacerbations and improve immune response to inhaled pathogens.
- Sector
- Healthcare
- HQ
- Reykjavik, Iceland
- Founded
- 2014
- Employees
- 9
- Website
- epiendo.com/
- Ownership
- Privately Held (backing)
EpiEndo Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EpiEndo Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EpiEndo Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.